HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Turnaround Strategies Wearing Well; Stock Gains 16% In Q2

This article was originally published in The Rose Sheet

Executive Summary

Avon's progress in implementing its turnaround initiatives, which has resulted in solid gains by the company's core U.S. beauty business, led the stock to a 15.7% advance to 46.28 in the second quarter.

You may also be interested in...



Avon Becoming Expected To Account For 10% Of Sales

Avon Becoming, the company's first retail initiative launching in Sears and J.C. Penney, is expected to generate 10% of sales, while Avon's traditional direct-sell business will account for 90%, Avon said.

Arden Gains Over 40% In Quarter As Firm Adds Class To Mass Distribution

Propelled by the early 2000 addition of a venerable name to its beauty products portfolio and a business more than doubled in size, Elizabeth Arden, formerly French Fragrances International, added 41% to its stock price in the first quarter.

Anew Retroactive Skin Cream Addresses Aging Through Cell Communication

Avon's Anew Retroactive age-reversing cream uses innovative technology to "attack aging at the cellular level," the company said at a press event in New York City June 6. Debuting in October, Retroactive is the "first skin care technology to attack aging where it starts," Avon maintains.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel